Related Experiment Video

Updated: Aug 11, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Decreased protein C activation in patients with fulminant hepatic failure

Michihiko Yamaguchi1, Esteban C Gabazza, Osamu Taguchi

  • 1Department of Internal Medicine, Division of Gastroenterology and Hepatology, Division of Pulmonary and Critical Care Medicine, Mie University School of Medicine, Edobashi, Tsu-city, Japan.

Scandinavian Journal of Gastroenterology
|February 25, 2006
PubMed

Insights

Fulminant hepatic failure (FHF) is linked to endothelial cell injury and reduced protein C (PC) activation, leading to hypercoagulability. This study highlights impaired PC pathway function in FHF patients.

Area of Science:

  • Hepatology
  • Coagulation Science
  • Endothelial Biology

Background:

  • Abnormalities in blood coagulation impact outcomes in fulminant hepatic failure (FHF).
  • The protein C (PC) pathway is a key regulator of coagulation, but its role in FHF remains unclear.
  • Endothelial cell injury is a significant factor in FHF pathogenesis.

Purpose of the Study:

  • To evaluate endothelial cell injury in FHF patients.
  • To assess the generation of activated protein C (APC) in FHF.
  • To investigate the relationship between the PC pathway and hypercoagulability in FHF.

Main Methods:

  • Analysis of plasma markers including thrombin-antithrombin complex and thrombomodulin.
  • Measurement of activated protein C-protein C inhibitor (APC-PCI) complex and APC-PCI/PC ratio.
  • In vitro assessment of APC's effect on tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1) expression in LI90 stellate cells.
  • Study included patients with FHF, acute hepatitis (AH), chronic hepatitis (CH), and healthy controls.

Main Results:

  • FHF patients exhibited significantly increased plasma concentrations of thrombin-antithrombin complex and thrombomodulin compared to AH patients and healthy subjects.
  • Circulating levels of APC-PCI complex and the APC-PCI/PC ratio were significantly decreased in FHF patients versus healthy controls.
  • Activated protein C (APC) demonstrated significant in vitro inhibition of TNF-alpha and MCP-1 expression in LI90 stellate cells.

Conclusions:

  • FHF is characterized by enhanced endothelial cell injury.
  • Decreased protein C (PC) activation contributes to hypercoagulability in FHF.
  • The findings suggest a critical role for PC pathway dysfunction in FHF pathophysiology.
Abstract

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...